Sugi Predict

Sugi Predict / Targets / CACNA2D3

CACNA2D3

Voltage-dependent calcium channel subunit alp · Q8IZS8 · CACNA2D3 on Sugi Atlas →

6,268 patent compounds predicted against CACNA2D3, 2,581 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL116362 SCHEMBL116362 0.45 11/20
SCHEMBL6121858 SCHEMBL6121858 0.52 9/20
SCHEMBL2585915 SCHEMBL2585915 0.51 8/20
SCHEMBL3354274 SCHEMBL3354274 0.62 7/20
SCHEMBL3357851 SCHEMBL3357851 0.54 7/20
SCHEMBL4750473 SCHEMBL4750473 0.52 7/20
SCHEMBL3350921 SCHEMBL3350921 0.49 7/20
SCHEMBL619154 SCHEMBL619154 0.41 7/20
SCHEMBL620978 SCHEMBL620978 0.40 7/20
SCHEMBL621013 SCHEMBL621013 0.40 7/20
SCHEMBL5428566 SCHEMBL5428566 0.52 6/20
SCHEMBL621555 SCHEMBL621555 0.39 6/20
SCHEMBL617973 SCHEMBL617973 0.38 6/20
SCHEMBL4405461 SCHEMBL4405461 0.55 5/20
SCHEMBL4399845 SCHEMBL4399845 0.54 5/20
SCHEMBL4967687 SCHEMBL4967687 0.51 5/20
SCHEMBL1810921 SCHEMBL1810921 0.51 5/20
SCHEMBL4399843 SCHEMBL4399843 0.50 5/20
SCHEMBL3477582 SCHEMBL3477582 0.47 5/20
SCHEMBL3353571 SCHEMBL3353571 0.47 5/20

Clinical trials — most relevant to CACNA2D3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effect of Pregabalin and Etoricoxib on Pain Alone Versus in Combination PHASE4UNKNOWN
4-Aminopyridine in Episodic Ataxia Type 2 PHASE2WITHDRAWN
Efficacy and Safety of Neridronate (Nerixia®)to Treat Osteoporosis in Patients With TM and TI PHASE2COMPLETED
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients PHASE2WITHDRAWN
Calcium Channel Blockade in Primary Aldosteronism PHASE2COMPLETED
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease PHASE2COMPLETED
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients PHASE2WITHDRAWN
A Phase I/II, First-In-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Activity to Prevent or Treat Neuropsychiatric Symptoms in Pediatric Subjects With Timothy Syndrome PHASE1/PHASE2NOT_YET_RECRUITING
Multicenter Study of Patients With SHANK3 Mutations: Identification of Genes Modificators in Phelan-McDermid Syndrome (EUQ13) nanNOT_YET_RECRUITING
Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development nanRECRUITING
Calciotropic Effects After HCG Stimulation Test nanCOMPLETED
MRI-phenotyping of Patients With Pathogenic Anoctamin 5 Variants nanRECRUITING
Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease nanUNKNOWN
Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy nanCOMPLETED
Urine Concentration of S100B in Extremely Premature Infants nanCOMPLETED
Genetic Determinants of Sudden Cardiac Death nanCOMPLETED
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives nanUNKNOWN
United States Hypophosphatasia Molecular Research Center nanCOMPLETED
Sodium Channel Splicing in Obstructive Sleep Apnea (SOCS-OSA) nanCOMPLETED
Assessing Bone Calcium Content in Children With Kidney Disease Treated With Two Different Medicines nanUNKNOWN
Sodium Channel Splicing in Heart Failure Trial nanCOMPLETED
Unraveling Genetics of HypoPhosPhatasia (HPP Genetics) nanCOMPLETED
Artificial Intelligence for the Prioritization of Genetic Background in Brugada Syndrome nanCOMPLETED
Human Epilepsy Genetics--Neuronal Migration Disorders Study nanRECRUITING
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services nanUNKNOWN
Follow-up of a Cohort of Patients With Myasthenic Syndrome and COVID-19 Infection nanCOMPLETED
Development of an Artificial Intelligence Algorithm to Detect Pathological Repolarization Disorders on the ECG and the Risk of Ventricular Arrhythmias nanRECRUITING
Multidisciplinary Study of Right Ventricular Dysplasia nanCOMPLETED
The Influence of Genetic Predisposition on Outcome After Catheter Ablation of Atrial Fibrillation. nanUNKNOWN
Genetic Mapping of Atherogenic Lipoprotein Phenotypes nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CACNA2D3 binder may also engage these)

ProteinNameSimilarity
Q8CFG5 — 1.000 Q8CFG5 →
Q9Z1L5 — 1.000 Q9Z1L5 →
Q5RJF7 — 0.998 Q5RJF7 →
CACNA2D4 Voltage-dependent calcium channel subunit alp 0.993 landscape →
A8XP97 — 0.988 A8XP97 →
P34374 — 0.986 P34374 →
ITGB1 Integrin beta-1 0.983 landscape →
A8WPG9 — 0.982 A8WPG9 →
P11584 — 0.981 P11584 →
Q23681 — 0.981 Q23681 →
O94910 — 0.981 O94910 →
Q9GYQ4 — 0.980 Q9GYQ4 →
O16544 — 0.980 O16544 →
Q7JQ32 — 0.980 Q7JQ32 →
V9ZAY0 — 0.980 V9ZAY0 →
O88923 — 0.980 O88923 →
A0M8R7 — 0.979 A0M8R7 →
Q03145 — 0.979 Q03145 →
O97831 — 0.979 O97831 →
A3QM97 — 0.979 A3QM97 →
MET Hepatocyte growth factor receptor 0.978 landscape →
Q90344 — 0.978 Q90344 →
Q09YH7 — 0.978 Q09YH7 →
P19823 — 0.978 P19823 →
Q2EI26 — 0.978 Q2EI26 →
O77633 — 0.978 O77633 →
Q98TB4 — 0.977 Q98TB4 →
Q4V8F8 — 0.977 Q4V8F8 →
Q94316 — 0.977 Q94316 →
J9Z332 — 0.977 J9Z332 →